Skip to main content

Table 2 Current treatment, relapsing, disease status, death, neoplasia, and follow-up of patients with dermatomyositis

From: The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis

  Anti-Jo-1 (+)
(n = 10)
Anti-Jo-1 (−)
(n = 108)
P value
Treatment
 Prednisone
  Current use 7 (70.0) 32 (29.6) 0.015
  Current dose (mg/day) 15 [5–40] 10 [5–40] 0.788
 Immunosuppressive drugs 10 (100.0) 63 (58.3) 0.013
  Methotrexate 3 (30.0) 27 (25.0) 0.715
  Azathioprine 1 (10.0) 22 (20.4) 0.684
  Mycophenolate mofetil 5 (50.0) 14 (13.0) 0.010
  Cyclosporine 1 (10.0) 6 (5.6) 0.471
  Leflunomide 1 (10.0) 7 (6.5) 0.519
  Intravenous immunoglobulin 1 (10.0) 1 (0.9) 0.163
  Rituximab 2 (20.0) 11 (10.2) 0.307
Disease relapse 7 (70.0) 56 (51.9) 0.508
Current disease status
 Disease remission 0 38 (35.2)
 Complete clinical response 2 (20.0) 32 (29.6) 0.722
 Disease activity 0 10 (9.3)
Death 1 (10.0) 9 (8.3) > 0.999
Neoplasia 0 0
Follow-up 10 (100.0) 58 (53.7) 0.005
  1. Data are shown as medians [interquartile ranges] or number of patients (%)